Strata Skin Sciences Inc SEC Filings

Strata Skin Sciences, Inc. Schedule 13G discloses that CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. together report beneficial ownership of 365,849 shares, representing 6.9% of the outstanding common stock (based on 5,268,708 shares outstanding per the Company prospectus supplement). The filing shows no sole voting or dispositive power and records shared voting and dispositive power over all reported shares. Heights Capital is identified as investment manager and authorized agent for CVI Investments via a limited power of attorney.

Accelmed Partners and affiliated reporting persons disclose beneficial ownership of 1,441,835 shares of Strata Skin Sciences common stock, representing 27.4% of the outstanding shares. This Amendment No. 2 to Schedule 13D reports that the percentage calculation is based on 5,268,708 shares outstanding following a September 4, 2025 registered direct offering by the issuer that issued 1,097,547 new shares. The filing amends prior Schedule 13D information solely to reflect the change in percent of class; no transactions in the issuer's shares by the reporting persons occurred in the past 60 days. The reporting persons and signatory for this filing is Uri Geiger in his capacity as Managing Partner.

Lincoln Alternative Strategies LLC reported beneficial ownership of 365,849 shares of Strata Skin Sciences, Inc. common stock, representing 6.94% of the outstanding shares based on 5,268,708 shares outstanding as of September 3, 2025. The filing is a Schedule 13G indicating passive ownership under the Exchange Act rules and expressly certifies the shares were not acquired to change or influence control of the issuer. The reporting entity is organized in Delaware and lists its principal business address in Miami Beach, FL. The filing was signed by Stephen Temes as Managing Member on September 4, 2025.

Strata Skin Sciences (SSKN) is offering securities under a prospectus supplement that contemplates sales of common stock at $2.204 per share and a variety of other instruments including preferred stock, debt securities, warrants, rights and units. The company estimates net proceeds of approximately $2.15 million after placement agent fees and offering expenses and intends to use proceeds for working capital and general corporate purposes. The supplement references risk factors and forward-looking statements and incorporates prior SEC reports including annual and quarterly filings and current reports filed through September 3, 2025. The prospectus describes detailed terms that may apply to each security type, including conversion, payment, redemption and tax considerations, and lists distribution methods such as underwriters, agents, direct sales and block trades.

Strata Skin Sciences, Inc. disclosed that on August 19, 2025 Nasdaq notified the company it is not in compliance with the Nasdaq Capital Market minimum stockholders' equity requirement of $2,500,000. The company's Quarterly Report for the quarter ended June 30, 2025 reported stockholders' equity below that threshold and the company does not meet alternative Nasdaq standards related to market value of listed securities or net income from continuing operations.

The Notice does not immediately affect the listing and the common stock continues trading under the symbol SSKN. Nasdaq gave Strata 45 calendar days, until October 3, 2025, to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days from the Notice date to evidence compliance. The company is evaluating options and plans to timely submit a plan, but stated there is no assurance the plan will be accepted or that compliance will be achieved.